Ipilimumab for patients with advanced mucosal melanoma

Oncologist

Volumn 18, Issue 6, 2013, Pages 726-732

  Postow, Michael A ^a   Luke, Jason J ^d   Bluth, Mark J ^b   Ramaiya, Nikhil ^e   Panageas, Katherine S ^c   Lawrence, Donald P ^f   Ibrahim, Nageatte ^d   Flaherty, Keith T ^f   Sullivan, Ryan J ^f   Ott, Patrick A ^d   Callahan, Margaret K ^a   Harding, James J ^a   D'Angelo, Sandra P ^a   Dickson, Mark A ^a   Schwartz, Gary K ^a   Chapman, Paul B ^a   Gnjatic, Sacha ^g,h   Wolchok, Jedd D ^a   Stephen Hodi, F ^d   Carvajal, Richard D ^a  

^a Departments of Preventive Medicine   (United States)

^b Departments of Psychiatry   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^g LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer testis antigens; CTLA 4; Immunotherapy; Ipilimumab; Mucosal melanoma

Indexed keywords

B RAF KINASE; IPILIMUMAB; NY ESO 1 ANTIGEN; PROTEIN P53; STEROID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; MALE; MELANOMA; MUCOSAL MELANOMA; MULTICENTER STUDY (TOPIC); ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; THYROIDITIS; TUMOR VOLUME;

CANCER-TESTIS ANTIGENS; CTLA-4; IMMUNOTHERAPY; IPILIMUMAB; MUCOSAL MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84879496727     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0464     Document Type: Article

References (29)

1. Patel SG, Prasad ML, Escrig M et al. Primarymu-cosal malignant melanoma of the head and neck. Head Neck 2002;24:247-257.
2. Yeh JJ, Shia J, Hwu WJ et al. The role ofabdomi-noperineal resection assurgical therapyforanorec-tal melanoma. Ann Surg 2006;244:1012-1017.
3. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364: 2517-2526.
4. Hodi FS, O'Day SJ, McDermott DF et al. Im proved survival with ipilimumab in patients with metastatic melanoma. N Engl JMed 2010;363:711-723.
5. Del Vecchio M, Simeone E, Chiarion Sileni Vet al. Efficacy and safety of ipilimumab in patients with pretreated, mucosal melanoma: Experience from Italian clinics participating in the European Expanded Access Programme. ESMO 2012:Abstract 1130P.
6. Lawrence D, McDermott D, Hamid O et al. Treat-ment of patients (pts) with stage III or IV melanoma on an ipilimumab (Ipi) expanded access program (EAP): Results for 3mg/kg cohort. Presented at the Ninth International Congress of the Society for Melanoma Research, Hollywood, CA; November 8,2012.
7. Antonescu CR, Busam KJ, Francone TDet al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer2007;121:257-264.
8. Wolchok JD, Hoos A, O'Day Set al. Guidelinesfor the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
9. Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Bethesda, MD: National Cancer Institute, May 2009. Available at http://evs.nci. nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ Quick Reference_5x7.pdf. Accessed May12,2013.
10. Gnjatic S, Old LJ, Chen YT. Autoantibodies against cancer antigens. Methods Mol Biol 2009; 520:11-19.
11. Hersh EM, O'Day SJ, Powderly Jet al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011;29: 489-498.
12. Wolchok JD, Neyns B, Linette G et al. Ipili-mumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
13. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebo-controlled, phase II studycomparingthetolerabilityand efficacyofip-ilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-5598.
14. Yi JH, Yi SY, Lee HR et al. Dacarbazine-based chemotherapyasfirst-linetreatmentin noncutane-ous metastatic melanoma: Multicenter, retrospective analysis in Asia. Melanoma Res 2011;21:223-227.
15. Kim KB, Sanguino AM, Hodges C et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer2004;100:1478-1483.
16. Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res 2004;14:517-520.
17. Bartell HL, Bedikian AY, Papadopoulos NE et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 2008;30: 1592-1598.
18. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516.
19. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
20. Curtin JA, Fridlyand J, Kageshita Tet al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147.
21. Maldonado JL, Fridlyand J, Patel H et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003;95:1878-1890.
22. Curtin JA, Busam K, Pinkel Det al. Somaticacti-vation of KITindistinctsubtypesofmelanoma. JClin Oncol 2006;24:4340-4346.
23. Rivera RS, Nagatsuka H, Gunduz M et al. C-kit proteinexpression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008;452:27-32.
24. Jakob JA, Bassett RL, Ng CS et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118:4014-4023.
25. Ray-Coquard I, Cropet C, Van Glabbeke M et al. Lymphopenia as a prognosticfactorforoverall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009;69:5383-5391.
26. Shahabi V, Whitney G, Hamid O et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 2012;61: 733-737.
27. Chen YT, Chadburn A, Lee Pet al. Expressionof cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc Natl Acad Sci USA2010;107:3093-3098.
28. Chen YT, Hsu M, Lee Pet al. Cancer/testis antigen CT45: Analysis of m RNAand protein expression in human cancer. Int J Cancer 2009;124: 2893-2898.
29. Ishida T, Obata Y, Ohara N et al. Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its im-munogenicity. Cancer Immun 2008;8:15.